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Treatment of Paget's Bone Disease 
with the Bisphosphonate APDt 
Carlos A. Mautalen, M D * 
Thirty-two patients with Paget's bone disease have been 
treated with the bisphosphonate APD. Nineteen had pre-
viously received treatment for Paget's disease with EHDP 
alone or in combination with calcitonin; 13 had not pre-
viously received treatment for Paget's disease. APD was 
given in a mean dose of 6.8 mg/kg of body weight during 
a period of 6 to 12 months. Bone pain disappeared or 
diminished in 91% ofthe patients. A very significant dim-
inution ofthe biochemical indices of bone turnover was 
observed in all patients, but the response occurred faster 
in patients who had not previously received treatment for 
Paget's disease. In 10 patients, APD therapy was discon-
tinued after biochemical remission of the Paget's disease 
had been achieved. In most patients, clear signs of reacti-
vation of the disease appeared 9 to 10 months after APD 
therapy was discontinued. 
Several drugs, such as calcitonin (1), disodium EHDP (2-4), 
CI2MDP (5,6), or APD (7-9)t are used to treat patients with 
Paget's bone disease. However, none of these drugs per-
manently controls the disease, and in many cases the 
patient must be retreated when clinical symptoms recur 
and/or a reaction to the biochemical indices used to esti-
mate the activity of the disease reappears. 
In the present study we assessed the therapeutic efficacy 
of APD in the treatment of Paget's disease. We have 
separately evaluated patients who were previously un-
treated and patients whose disease had recurred fol low-
ing previous therapy. 
Patients and Methods 
We studied 32 patients with Paget's bone disease. There 
were 20 women and 12 men, ranging in age between 52 
and 76 years (average: 65.3 years). Thirteen patients had 
not previously received specific treatment for Paget's 
bone disease, while 19 patients had previously been 
treated. In 10 patients the treatment consisted of EHDP 
alone, and in nine cases the treatment was a combination 
of EHDP and calcitonin. In this group of 19, an unsatisfac-
t N o t e on the nomenclature: The tradit ional abbreviat ions for ident i fy ing com-
pounds have been used in the text. Accord ing to lUPAC, Nomenclature of 
Organic Chemistry, Sections A-H (Oxford : Pergamon Press, 1979), the new 
abbreviations are as fo l lows; 
APD = AHPpBP: 3-Amino-1-hydroxypropy l idene-1,1-b isphosphonate 
EHDP = HEBP; 1-Hydroxyethyl idene-1,1-bisphosphonate 
C I^MDP = CI^MBP: Dich loromethy lenebisphosphonate 
tory clinical or biochemical response to the former 
treatment led to the use of APD. The time interval 
between the suspension of the previous treatment and 
beginning of APD administration ranged from one to 
eight months with an average of 3.5 months. 
The APD was given in tablets of 100 mg, half an hour 
before meals. The daily dose per ki logram of body 
weight was 4-8 mg (average: 6.8 mg). Patients who were 
previously untreated received APD for a min imum of 
six months. The treatment was prolonged when bio-
chemical indices were not normal after six months. 
Previously treated patients received APD for a min-
imum of nine months. 
Serum alkaline phosphatase was measured by the 
met hod of King and Armstrong (normal values up to 15 
U/ml ) , and the total urinary hydroxyprol ine was meas-
ured by the method of Kivir icko, et al (normal values 
15-40 mg/24 hrs). 
Results 
Clinical symptoms 
Of the 32 patients, 23 had skeletal pain at the beginning 
of treatment. In 21 patients (91%), pain diminished or 
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disappeared on APD therapy; it remained unchanged in 
two cases. 
Al though systematic radiological examination was not 
performed, five patients showed definite radiological 
improvement of bone lesions in the fol lowing sites: 
femur (2 cases); tibia (2 cases); and dorsolumbar spine 
(one patient). 
Biochemical effect 
The effect of APD on serum alkaline phosphatase activity 
is given in Table I. In patients who had not previously been 
treated for Paget's disease, alkaline phosphatase was sig-
nificantly reduced within two months. In patients who had 
previously been treated, alkaline phosphatase did not 
drop significantly until the fourth month of therapy. The 
maximum decline was achieved at six months in the pre-
viously untreated patients and at 12 months in patients 
who had previously been treated. The nadir in alkaline 
phosphatase did not significantly differ between the two 
groups of patients. A similar pattern was obtained with the 
measurement of hydroxyproline excretion (Table II). 
A complete biochemical remission of the Paget's bone 
disease, as judged by the urine hydroxyproline excretion, 
was obtained in 10 of the 13 patients who had not pre-
viously been treated; the remaining three patients had a 
partial response. In patients who had previously been 
treated, seven obtained a complete remission, 11 a partial 
remission, and one patient failed to respond. In patients 
who had been previously untreated, the degree of bio-
chemical remission was directly related to the pretreat-
ment urine hydroxyproline excretion. In the previously 
treated patients, even though the basal urinary hydroxy-
proline of the patients with complete responses was sig-
nificantly lower than that of the patients with partial 
responses, there was some overlap between both groups. 
TABLE I 
The Effect of APD on the Serum Alkal ine Phosphatase in Patients wi th Paget's Bone Disease 
Before 
Units Treatment 2 mo 4 mo 6 mo 9 mo 12 mo 
WPT 
Wi thout previous K.A.U. 62.1 + 11.7 32.3 ± 7.7t 25.5 ± 6.8t 22.1 ± 5.0t 
treatment (13 pts) % 100 53.3 ± 6.0 43.6 ± 6.1 38.1 ± 4.2 
PT 
Previously K.A.U. 73.9 ± 8 . 5 70.8 ± 10.0 56.4 ± 8.2t 47.2 ± 6.5t 40.8 ± 6.4t 31.1 ± 6.9t 
treated (19 pts) % 100 91.8 ± 58** 71.9 ± 5.0* 59.3 + 5.4* 47.e ± 4.9 36.7 + 4.4 
* p Z 0.01 compared with WPT patients 
* p / 0.001 compared with WPT patients 
t p Z 0.01 compared wi th the initial values (paired t test) 
t p Z 0.001 compared with the initial values (paired t test) 
TABLE II 
The Effect of APD on the Urinary Ftydroxyproline Excretion in Patients wi th Paget's Bone Disease 
Before 
Units Treatment 2 mo 4 mo 6 mo 9 mo 12 mo 
WPT 
Wi thout previous mg/24hs 137.4 ± 30.0 70.4 ± 17.4t 58.1 ± 14.5t 50.3 ± 13.1§ 
treatment (13 pts) % 100 53.3 ± 5.6 43.4 ± 3.8 39.0 ± 4.0 
PT 
Previously mg/24hs 141.8 ± 16.0 132.5 ± 19.1 117.2 ± 18.9t 107.4 + 17.71 98.2 ± 15.2§ 83.4 + 14.2§ 
treated (19 pts) % 100 88.0 ± 5.4** 78.0 ± 6.9** 70.9 ± 7.9* 58.2 + 4.9 46.9 + 3.6 
* p Z0.01 compared wi th WPT patients 
** p Z 0.001 compared with WPT patients 
t p Z 0.05 compared with the initial values (paired t test) 
t p Z 0.01 compared with the initial values (paired t test) 
§ p Z 0.001 compared wi th the initial values (paired t test) 
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Fig.1 
Patient wi th Paget's bone disease of the skull. 
He had been treated wi th EHDP in Ihe dose indicated. APD in doses of 
4.7 mg/kg /day produced for the first t ime a biochemical remission 
wi th in the normal range. (The dark zone in this f igure and the fo l lowing 
ones indicates the normal range.) The dose in m g / k g of body weight is 
shown above the hatched areas. 
I n 19 cases, the efficacy of APD was evaluated in relation to 
the first series of treatment with other drugs. Eleven 
patients had been given EHDP, seven had received EHDP 
combined with calcitonin, and one patient had received 
calcitonin only. The response was better in 47% of the 
cases, similar in 32%, and worse in 21%. Eleven of the 19 
had received a second course of therapy before APD 
treatment. Six had received EHDP alone, four EHDP and 
calcitonin, and one calcitonin alone for the second 
treatment. APD was more effective in 73% of the patients 
and similar in the remaining 27%. The pattern of the 
biochemical response in four illustrative cases who had 
been previously treated before APD therapy is given in 
Figs. 1-4. 
Persistence of biochemical remission 
Measurements of serum alkaline phosphatase and hydroxy-
proline excretion were performed in 10 patients after 
interrupt ion of APD treatment. The period of observa-
t ion ranged between three and 15 months. The effect of 
APD was maintained during the first three to six months 
in most patients (Fig. 5). However, nine to 10 months 
after the suspension of treatment, clear signs of reactiva-
tion were observed in most of the examined patients. 
Fig. 2 
Patient wi th Paget's disease of the left t ibia. 
The treatment wi th APD decreased the serum alkaline phosphatase 
into the normal range, unl ike former treatments. A marked radiologi-
cal remineral izat ion was observed. Nine months after suspension of 
APD, a significant increase of urinary hydroxyprol ine occurred. 
Comparison of the effect of APD with previous therapy 
The response to APD therapy was considered better or 
worse than the previous therapy when the minimum 
value for urinary hydroxyprol ine obtained during treat-
ment with APD was at least 20% lower or higher than the 
min imum value observed dur ing previous treatment. 
Otherwise, the response was considered "similar". 
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Fig. 3 
Patient wi th polyostotic bone disease. 
Treatment wi th APD produced a greater b iochemical remission than 
previous treatments wi th EHDP. 
246 
Paget's Bone Disease with the Bisphosphonate APD 
Discussion 
The treatment of Paget's bone disease with APD in 
patients who had not previously received a specific 
treatment caused a satisfactory clinical and biochemical 
response similar to that found by other authors (7-9). 
However, unlike the previous studies (7,8), the biochem-
ical indices did not decrease into the normal range in all 
patients. Table III clearly shows that the ability of APD 
treatment to produce a decrease of the biochemical 
values within the normal range was related to the basal 
level of urinary hydroxyproline excretion. A complete 
remission was observed in all patients with hydroxypro-
line excretions lower than 150 mg/24 hrs, while in 
patients with excretions higher up to 200 mg/24 hrs, the 
decrease, while significant, did not reach normal levels. 
Similarly, Nagant de Deuxchaisnes (8) found that after 
treatment with APD, the serum alkaline phosphatase 
decreased to normal values in those patients whose pre-
treatment levels were lower than 140IU/1, while such 
normalization was not attained when the basal level was 
higher than 200 IU/1 (normal up to 60 lU/1). 
The effect of APD upon the biochemical indices was signif-
icantly slower in the patients who a few months earlier had 
received EHDP alone or in combination with calcitonin. 
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Fig. 4 
Patient wi th Paget's bone disease of the skul l , lumbar and dorsal spine, 
and pelvis. 
The combined treatment wi th EHDP and calcitonin 100 IU three times a 
week induced a good biological effect, but the biochemical index 
reached the normal range dur ing APD administrat ion. 
TABLE III 
Relationship between Biological Response to APD 
and Activity of Paget's Bone Disease 
Judged by Urinary Hydroxyprol ine Excretion before Treatment 
Biological Response (mg/24hrs) 
Groups 
Response 
Av. ± 1SEM 
range 
WPT 
Without THP 
previous 
treatment (13 pts) Response 
PT 
Previously THP 
treated (19 pts) 
Av. ± 1SEM 
range 
Complete Partial 
10 3 
82.1 + 9.7 315.0 + 44.8" 
(47 - 151) (227 -416) 
7 11 
74.7 + 10.4 176.4 + 16.8' 
(53 - 126) (78 - 257) 
Absent 
0 
1 
230 
* p Z0.001 compared with patients wi th complete biological response 
Since APD occupies the same binding sites of EHDP in the 
hydroxyapatite crystals, it is feasible that this last com-
pound may have initially prevented the effect of APD. 
However, when the administration of APD was pro-
longed, a satisfactory result was obtained in most patients. 
Previous reports (8-11) indicated that APD has the advan-
tage over EHDP of inducing radiological improvement in 
the skeletal segments affected by Paget's bone disease. In 
% FINAL 
VALUE 
t e O r 
150 -
140 
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110 
100 
URINARY HYDROXYPROLINE 
SERUM ALKALINE PHOSPHATASE 
MONTHS 
Fig. 5 
Changes of the serum alkaline phosphatase and the urinary excret ion 
of hydroxyprol ine after the in ter rupt ion of APD administrat ion. Values 
are expressed asa percentage of the final levels dur ing APD treatment. 
The number of observations is indicated in parentheses. 
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this study marked radiological improvements in some of 
the treated patients were observed. In addition, it has been 
observed that APD caused greater biochemical remissions, 
compared to those induced by EHDP, except when this 
compound was used in a high dose, which exacerbates 
bone pain and significantly inhibits bone mineralization 
(12). Likewise, better results have been observed (13) with 
APD than those obtained in the same patients with the 
association of EHDP in an average dose of 6.5 mg/kg/day 
and salmon calcitonin (100 IU twice a week). 
Although the number of patients observed in our study is 
small, the present study does not confirm former results 
(10) indicating that the biochemical remissions induced 
by APD are prolonged. Nine months after treatment sus-
pension, a high percentage of recurrences was observed. 
The basal urinary hydroxyproline excretion levels suggest 
that the presently evaluated patients were more severely 
affected than those described by Frjlink, et al (7). This may 
explain the faster elevation of the biochemical controls 
after the treatment was interrupted. Khairi, et al (2) have 
indicated that the severity of the disease before therapy is 
the most important factor influencing the postsuspension 
relapses after treatments with EHDP. 
Calcitonin as well as compounds of the diphosphonate 
family have proven effective in inhibiting the accelerated 
bone turnover of Paget's bone disease. However, in most 
patients the obtained remissions are not sustained. Suc-
cessive series of treatment separated by variable time 
intervals are required to control the disease. The present 
study showed that APD is an effective treatment from the 
clinical, radiological, and biochemical poipt of view, not 
only for patients who had not been previously treated, but 
also for those already treated with EHDP and/or calcitonin. 
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